Johnson & Johnson is selling its Ortho-Clinical Diagnostics (OCD) business to global alternative asset manager The Carlyle Group in a transaction that comes to some $4.15 billion and is expected to close mid year.
Background
Johnson & Johnson’s OCD business is a global provider of solutions for screening, diagnosing, monitoring and confirming diseases and is focused on supporting hospitals, laboratories and blood centers worldwide. Headquartered in Raritan, NJ, with manufacturing operations in Rochester, NY, Pompano Beach, FL and Pencoed, Wales, OCD operates in 130 countries.
Equity for the transaction comes from Carlyle Partners VI, a $13 billion U.S. Buyout fund, which completed fundraising in November 2013 with two hundred and sixty-nine investors from 43 countries.
Company comments
for The Carlyle Group
Stephen H. Wise, Managing Director of The Carlyle Group, said, “Ortho-Clinical Diagnostics is an established global brand with a reputation for quality and innovation. Through accelerated investment in research and product development and continued expansion into both emerging and established markets, we expect to tap into rising demand for sophisticated medical diagnostic products and services worldwide. We have been focused on the diagnostics industry for many years given its attractive growth prospects, driven by the crucial role it plays in health care decision-making and influencing patient outcomes. We believe that OCD, with its world class employee base and talented management team, is poised for the next level of success.”
for Johnson and Johnson OCD
Eric Compton, Worldwide President, Ortho-Clinical Diagnostics, said, “We are excited to work with Carlyle and believe OCD will be well-positioned as an independent company focused exclusively on the in vitro diagnostics market. In combination with Carlyle’s global reach and deep experience in the healthcare sector, OCD will have the opportunity to invest in new, innovative products and services for its customers and provide an environment for its professionals to excel in a competitive global marketplace.”
Source: The Carlyle Group, Business Wire
published: January 16, 2014 in: Johnson & Johnson, Mergers and Acquisitions